136 related articles for article (PubMed ID: 19366061)
1. Expression of ezrin and metastatic tumor antigen in osteosarcomas of the jaw.
Park HR; Cabrini RL; Araujo ES; Paparella ML; Brandizzi D; Park YK
Tumori; 2009; 95(1):81-6. PubMed ID: 19366061
[TBL] [Abstract][Full Text] [Related]
2. Prognostic significance of immunohistochemical expression of ezrin in non-metastatic high-grade osteosarcoma.
Ferrari S; Zanella L; Alberghini M; Palmerini E; Staals E; Bacchini P
Pediatr Blood Cancer; 2008 Apr; 50(4):752-6. PubMed ID: 17886294
[TBL] [Abstract][Full Text] [Related]
3. Phosphorylated ezrin is located in the nucleus of the osteosarcoma cell.
Di Cristofano C; Leopizzi M; Miraglia A; Sardella B; Moretti V; Ferrara A; Petrozza V; Della Rocca C
Mod Pathol; 2010 Jul; 23(7):1012-20. PubMed ID: 20348881
[TBL] [Abstract][Full Text] [Related]
4. Ezrin immunohistochemical expression in cartilaginous tumours: a useful tool for differential diagnosis between chondroblastic osteosarcoma and chondrosarcoma.
Salas S; de Pinieux G; Gomez-Brouchet A; Larrousserie F; Leroy X; Aubert S; Decouvelaere AV; Giorgi R; Fernandez C; Bouvier C
Virchows Arch; 2009 Jan; 454(1):81-7. PubMed ID: 19050913
[TBL] [Abstract][Full Text] [Related]
5. Ezrin in osteosarcoma: comparison between conventional high-grade and central low-grade osteosarcoma.
Park HR; Jung WW; Bacchini P; Bertoni F; Kim YW; Park YK
Pathol Res Pract; 2006; 202(7):509-15. PubMed ID: 16677779
[TBL] [Abstract][Full Text] [Related]
6. Clinicopathological and immunohistochemical analysis of twenty-five head and neck osteosarcomas.
Junior AT; de Abreu Alves F; Pinto CA; Carvalho AL; Kowalski LP; Lopes MA
Oral Oncol; 2003 Jul; 39(5):521-30. PubMed ID: 12747978
[TBL] [Abstract][Full Text] [Related]
7. Analysis of p53 expression in osteosarcoma of the jaw: correlation with clinicopathologic and DNA ploidy findings.
Oliveira P; Nogueira M; Pinto A; Almeida MO
Hum Pathol; 1997 Dec; 28(12):1361-5. PubMed ID: 9416691
[TBL] [Abstract][Full Text] [Related]
8. Clinical significance of microRNA-183/Ezrin axis in judging the prognosis of patients with osteosarcoma.
Mu Y; Zhang H; Che L; Li K
Med Oncol; 2014 Feb; 31(2):821. PubMed ID: 24352761
[TBL] [Abstract][Full Text] [Related]
9. Ezrin expression predicts survival in stage IIB osteosarcomas.
Kim MS; Song WS; Cho WH; Lee SY; Jeon DG
Clin Orthop Relat Res; 2007 Jun; 459():229-36. PubMed ID: 17353802
[TBL] [Abstract][Full Text] [Related]
10. Primary versus radiation-associated craniofacial osteosarcoma: Biologic and clinicopathologic comparisons.
McHugh JB; Thomas DG; Herman JM; Ray ME; Baker LH; Adsay NV; Rabah R; Lucas DR
Cancer; 2006 Aug; 107(3):554-62. PubMed ID: 16795069
[TBL] [Abstract][Full Text] [Related]
11. Ezrin and alpha-smooth muscle actin are immunohistochemical prognostic markers in conventional osteosarcomas.
Salas S; Bartoli C; Deville JL; Gaudart J; Fina F; Calisti A; Bollini G; Curvale G; Gentet JC; Duffaud F; Figarella-Branger D; Bouvier C
Virchows Arch; 2007 Dec; 451(6):999-1007. PubMed ID: 17786474
[TBL] [Abstract][Full Text] [Related]
12. Ezrin immunohistochemical expression in chondrosarcomas, osteosarcomas and Ewing sarcoma family of tumors.
Machado I; Navarro S; Giner F; Alberghini M; Bertoni F; Llombart-Bosch A
Virchows Arch; 2010 Jul; 457(1):87-9. PubMed ID: 20552365
[No Abstract] [Full Text] [Related]
13. Correlation of the Rac1/RhoA pathway with ezrin expression in osteosarcoma.
Chiappetta C; Leopizzi M; Censi F; Puggioni C; Petrozza V; Rocca CD; Di Cristofano C
Appl Immunohistochem Mol Morphol; 2014 Mar; 22(3):162-70. PubMed ID: 24614149
[TBL] [Abstract][Full Text] [Related]
14. The Prognostic Role of Ezrin and HER2/neu Expression in Osteosarcoma.
Abdou AG; Kandil M; Asaad NY; Dawoud MM; Shahin AA; Abd Eldayem AF
Appl Immunohistochem Mol Morphol; 2016; 24(5):355-63. PubMed ID: 26067138
[TBL] [Abstract][Full Text] [Related]
15. Expression change of ezrin as a prognostic factor in primary osteosarcoma.
Wang YF; Shen JN; Xie XB; Wang J; Huang G
Med Oncol; 2011 Dec; 28 Suppl 1():S636-43. PubMed ID: 20859706
[TBL] [Abstract][Full Text] [Related]
16. Immunoexpression of Ezrin and CD44 in patients with osteosarcoma.
Boldrini E; Peres SV; Morini S; de Camargo B
J Pediatr Hematol Oncol; 2010 Aug; 32(6):e213-7. PubMed ID: 20562647
[TBL] [Abstract][Full Text] [Related]
17. Amplification and protein expression of chromosome 12q13-15 genes in osteosarcomas of the jaws.
Lopes MA; Nikitakis NG; Ord RA; Sauk J
Oral Oncol; 2001 Oct; 37(7):566-71. PubMed ID: 11564577
[TBL] [Abstract][Full Text] [Related]
18. Expression of hormonal receptors in osteosarcomas of the jaw bones: clinico-pathological analysis of 21 cases.
Domínguez-Malagón HR; González-Conde E; Cano-Valdez AM; Luna-Ortiz K; Mosqueda-Taylor A
Med Oral Patol Oral Cir Bucal; 2014 Jan; 19(1):e44-8. PubMed ID: 24121902
[TBL] [Abstract][Full Text] [Related]
19. The prognostic value of elevated ezrin in patients with osteosarcoma.
Lun DX; Hu YC; Xu ZW; Xu LN; Wang BW
Tumour Biol; 2014 Feb; 35(2):1263-6. PubMed ID: 24014052
[TBL] [Abstract][Full Text] [Related]
20. Metastasis-associated protein is a predictive biomarker for metastasis and recurrence in gastric cancer.
Okugawa Y; Mohri Y; Tanaka K; Kawamura M; Saigusa S; Toiyama Y; Ohi M; Inoue Y; Miki C; Kusunoki M
Oncol Rep; 2016 Oct; 36(4):1893-900. PubMed ID: 27574100
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
